A mycoplasma mutant strain and its preparation method and application

By inserting LoxP and FRT sites into the Mycoplasma genome and using a recombinant enzyme system, combined with CRISPR/Cas9 technology, the problem of insufficient mycoplasma genome engineering tools in the existing technology is solved, and efficient construction of gene-deficient Mycoplasma is achieved, suitable for a variety of people. Mycoplasma species and reduce the residual effects of exogenous genes, it is suitable for the preparation of live Mycoplasma vaccines.

CN118460446BActive Publication Date: 2024-11-15INNER MONGOLIA AUTONOMOUS REGION ACAD OF AGRI & ANIMAL HUSBANDRY SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410931671.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-15
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

The lack of effective tools in the engineering of Mycoplasma genomics has limited functional genomics methods, especially when building Mycoplasma mutant libraries and designing vaccines, and the existing methods are difficult to adapt to multiple Mycoplasma species, and the impact of exogenous gene residues is studied. .

Method used

Transposon inserts LoxP and FRT sites into the Mycoplasma genome, and combines with the recombinase system to construct gene-deletion Mycoplasma without exogenous gene expression through specific site recombination and base editing technology. The CRISPR/Cas9 system and cytosine are used to The base editor realizes gene knockout, deletes foreign genes, and forms an efficient Mycoplasma mutant strain.

Benefits of technology

The efficient construction of Mycoplasma mutant strain was achieved, which reduced the experimental cost and cycle, improved the purity of the gene-deleted strain and the proportion of expression of foreign genes, and was suitable for the preparation of live Mycoplasma vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118460446B_ABST
    Figure CN118460446B_ABST
Patent Text Reader

Abstract

The present invention provides a mycoplasma mutant strain and a preparation method and application thereof, wherein the mycoplasma mutant strain contains two LoxP and one FRT site at the same time, and the FRT site is located between the two LoxP sites; or contains one LoxP and two FRT sites at the same time, and the LoxP site is located between the two FRT sites; and the LoxP and FRT sites are located in a non-open reading frame. The present invention also includes a vector used for preparing mycoplasma mutant strains, a vector used for preparing single gene deletion strains, and a method for constructing single or multiple gene deletion strains. Furthermore, the present invention also provides a method for preparing gene-deficient mycoplasma without exogenous gene expression. Through the technical scheme of the present invention, various gene-deficient strains of interest can be efficiently prepared using FRT or LoxP sites. And gene-deficient mycoplasma without exogenous protein expression can be further prepared. Compared with the prior art, the present invention has low experimental cost, high experimental efficiency, short experimental cycle, and does not need to establish a mycoplasma deletion strain library first.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of genetic engineering, and specifically relates to a mycoplasma mutant strain and a preparation method and application thereof. Background Art

[0002] Since 2012, CRISPR-based genetic tools have revolutionized the field of genome engineering in eukaryotes and prokaryotes. Typical CRISPR-Cas9 tools are based on the Cas9 nuclease and are guided to a specific site by a single guide RNA (sgRNA). After DNA cleavage, repair occurs through different cellular mechanisms, including nonhomologous end joining (NHEJ) and homology-directed recombination (HDR). However, many bacteria, including mycoplasmas, lack efficient NHEJ and HDR repair mechanisms. Therefore, CRISPR-Cas9 tools can only be used as negative screening. Base editor systems (BEs) provide a way to overcome this problem. The system contains cytosine base editors (CBEs) and adenine base editors (ABEs) that can achieve conversions between cytosine (C) and thymine (T) and adenine (A) and guanine (G) nucleotides, respectively, without the need for template DNA and double-stranded DNA breaks. Cytosine base editors (CBEs) are made by fusing Cas9 nickase or catalytically inactive Cas9 (dCas9) with cytosine deaminase. The base editor targets a specific site through gRNA, and cytosine deaminase converts cytosine into uracil within a small editing window near the PAM site. Since the uracil DNA glycosylase (UDG) present in the body can recognize uracil and use the base excision repair pathway (BER) to repair uracil to cytosine, CBE also contains a uracil DNA glycosylase inhibitor (UGI) to improve the efficiency of base editing.

[0003] Site-specific recombination technology is an important molecular biology technology developed in the 1980s. It uses site-specific recombinase (SSR) to perform gene manipulation between the recombination target site (RTS) on the genome and exogenous DNA, which can achieve gene replacement, inversion and tissue-specific knockout. Commonly used site-specific recombinase systems include: FLP-FRT system and Cre-LoxP system. The FLP-FRT system is similar to the Cre-LoxP system, both of which are composed of a recombinase and a special DNA sequence. Among them, the FLP (flippase recombination enzyme) recombinase was discovered in yeast cells. Its gene is 1272bp in length, a 48kDa polypeptide monomer protein consisting of 423 amino acids. FRT is the recognition site of FLP recombinase, with a total length of 48bp, consisting of three 13bp reverse palindromic sequences and an 8bp spacer sequence. Cre (Cyclization Recombination Enzyme) recombinase was discovered from P1 phage in 1981. The gene coding region sequence is 1029bp long, consisting of 343 amino acids and a 38kDa polypeptide monomer protein. LoxP is the recognition site of Cre recombinase, which consists of two 13bp reverse palindromic sequences and an 8bp intermediate spacer sequence to form a 34bp sequence. The reverse palindromic sequences of FRT and LoxP are the recognition and binding regions of the recombinase, and the spacer sequence is the region where recombination occurs, which also determines the direction of the entire sequence. The result of the recombination depends on the direction of the two recognition sites. There are mainly the following possibilities: ① If the two recognition sites are located on one DNA chain and in the same direction, the recombinase can effectively delete the sequence between the two recognition sites; ② If the two recognition sites are located on one DNA chain but in opposite directions, the recombinase can induce sequence flipping between the two recognition sites; ③ If the two recognition sites are located on two different DNA chains or chromosomes, the recombinase can induce exchange of the two DNA chains or chromosomal translocation, that is, gene transposition; ④ If the four recognition sites are located on two different DNA chains or chromosomes, the recombinase can induce sequence exchange between the recognition sites.

[0004] Transposons are a type of mobile genetic factor that can autonomously move and insert into random sites in the host genome. This transposition property enables it to directly or indirectly cause gene rearrangement and genetic mutation. Mycoplasmas are a type of tiny bacteria. Their special feature is that they do not have a cell wall, but are wrapped by a three-layer cell membrane. Mycoplasmas usually need to parasitize other cells to grow and reproduce, so they are also called endophytes. Currently, the systems that can be used for genetic manipulation of mycoplasma genes are very limited. Only transposons Tn916 and Tn4001 can be used for mycoplasma transformation. Among them, Tn916 has insertion hotspots, so it is not suitable for the construction of transposon mutant libraries for mycoplasmas. Tn4001 is a 4.5Kb composite transposon that has been successfully used for the transformation of a variety of mycoplasma species. At present, the deletion mutant strain library of the target gene of mycoplasma is mainly constructed by random transposition of transposons, and the insertion inactivation strains of the target gene are screened in large quantities in the transposon mutant library. The construction of mycoplasma mutants can be used to explore the functional genes of the target phenotype, and can also be used to screen mycoplasma gene-deficient attenuated live vaccines.

[0005] Control strategies for mycoplasma disease vary from region to region and include regulation of animal movement and the use of antibiotics, vaccines, and ultimately culling. In the context of increasing antibiotic resistance and the relative lack of effective vaccines, a better understanding of the molecular basis of virulence and host-pathogen interactions is needed to improve treatment options and design more effective preventive methods. However, the limited number of effective genome engineering tools for many mycoplasmas restricts functional genomics approaches and hinders the production of rationally designed vaccines. In the past decade, cutting-edge genome engineering methods have been developed that rely on cloning mycoplasma genomes in yeast, which are then edited and transplanted into recipient cells using a variety of genetic tools. Although offering unparalleled possibilities for studying and redesigning complete genomes, these in-yeast methods may be difficult to adapt to other species and they remain limited to a few mycoplasmas. Moreover, recombinant mycoplasmas constructed using existing genetic engineering techniques often retain traces of exogenous genes, which often affects further research on mycoplasmas. Summary of the invention

[0006] Based on the problems existing in the prior art, the object of the present invention is to provide a mycoplasma mutant strain, wherein the mycoplasma mutant strain contains two LoxP sites and one FRT site at the same time, and the FRT site is located between the two LoxP sites; or contains one LoxP and two FRT sites at the same time, and the LoxP site is located between the two FRT sites; the LoxP and FRT sites are located in a non-open reading frame.

[0007] A method for preparing a mycoplasma mutant strain comprises using a transposon to insert two LoxP sites and one FRT site into a non-open reading frame in a mycoplasma genome, wherein the FRT site is located between the two LoxP sites; or inserting one LoxP and two FRT sites, wherein the LoxP site is located between the two FRT sites.

[0008] A vector containing a transposon comprises the following elements: a gene regulatory sequence, a transposase gene sequence, a left-directed terminal inverted repeat sequence, a forward LoxP recognition site, a forward FRT recognition site, a gentamicin resistance gene, and a right-directed terminal inverted repeat sequence.

[0009] Optionally, the gene regulatory sequence is shown in SEQ ID NO.7; the transposase is Tn4001 transposase, and the gene sequence is shown in SEQ ID NO.8; the left-terminal inverted repeat sequence is shown in SEQ ID NO.9; the forward LoxP recognition site sequence is shown in SEQ ID NO.10; the forward FRT recognition site sequence is shown in SEQ ID NO.11; the gentamicin resistance gene sequence is shown in SEQ ID NO.12; and the right-terminal inverted repeat sequence is shown in SEQ ID NO.13.

[0010] Preferably, the full sequence of the elements in the vector is shown as SEQ ID NO.14.

[0011] Application of the above vector in preparing mycoplasma mutant strains.

[0012] The mycoplasma mutant strain is used to prepare gene-deficient mycoplasma without exogenous gene expression.

[0013] An optional application is to use gene editing technology to knock out the target gene in the above mutant strain to construct a gene-deficient mycoplasma; then use a recombinase to delete the exogenous gene to obtain a gene-deficient mycoplasma without exogenous gene expression.

[0014] The present invention also provides a method for preparing a single gene deletion type mycoplasma, wherein a recombinant vector is transferred into the mutant strain as described above to construct a single gene deletion type mycoplasma; the recombinant vector comprises the following elements: a gene regulatory sequence, sgRNA, a gRNA backbone of the CRISPR / Cas9 system of Streptococcus pyogenes, a fibrin terminator, a cytosine base editor sequence, a forward LoxP or FRT recognition site, a tetracycline resistance gene, and a pUC replicon.

[0015] A method for preparing a multi-gene deletion type Mycoplasma, comprising constructing a sgRNA vector of multiple genes to be knocked out, transferring the vector into a single gene deletion type Mycoplasma prepared by the above method, and obtaining the multi-gene deletion type Mycoplasma by gene knockout.

[0016] The present invention also provides a method for preparing gene-deficient mycoplasma without exogenous gene expression, wherein a vector containing a recombinase is transferred into the mycoplasma prepared by the above method, and the exogenous gene is deleted by using the recombinase.

[0017] Beneficial effects of the present invention:

[0018] 1. The present invention utilizes transposons to prepare mycoplasma mutants containing both LoxP and FRT sites. Once the desired mycoplasma mutants are created, the FRT or LoxP sites can be efficiently used to prepare various gene deletion strains of interest.

[0019] 2. After obtaining the desired gene-deficient strain, two LoxP or FRT sites arranged in the same direction can be used to electroporate into the Cre or FLP recombinase plasmid to delete all exogenous genes introduced by transposition and recombination, leaving only a small amount of sequence, no exogenous protein expression, no antibiotic resistance, and can be further used for the preparation of mycoplasma live vaccine.

[0020] 3. Compared with the existing methods, this method does not require the establishment of a mycoplasma deletion strain library first, and then screens the required gene deletion strains after a large amount of single clone sequencing. The experimental cost is low, the experimental efficiency is high, and the experimental cycle is short. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 :flow chart.

[0022] Figure 2 : PUC-SP backbone vector map.

[0023] Figure 3 :pTn4001-GmR vector map.

[0024] Figure 4 :pCas9-FRT vector map.

[0025] Figure 5 : PCR identification of mycoplasma, positive PCR product 531bp, lanes from left to right are: 1 is DL2000bpMarker, 2-9 are 8 randomly selected mycoplasma colonies, and 10 is blank control.

[0026] Figure 6 : PCR identification of mycoplasma, positive PCR product 1188bp, lanes from left to right are: 1 is DL2000bpMarker, 2-9 are 8 randomly selected mycoplasma colonies, and 10 is blank control.

[0027] Figure 7: PCR identification of mycoplasma, PCR amplification of DnaJ product 609bp, lanes from left to right are: 1 is DL2000bpMarker, 2-9 are 8 randomly selected mycoplasma colonies, and 10 is a blank control.

[0028] Figure 8 : Comparison of sequencing results of the original strain and the preferred mutant strain.

[0029] Fig. 9 : The sequencing results of the preferred mutant strain showed that the insertion site was located between two open reading frames.

[0030] Fig.10 : Comparison of sequencing results before and after recombination.

[0031] Fig.11 : Comparison of sequencing results of Mycoplasma DnaJ gene deletion strains.

[0032] Fig.12 : Sequencing results of gene-deficient mycoplasma without exogenous gene expression. DETAILED DESCRIPTION

[0033] The present invention provides a mycoplasma mutant strain, wherein the mycoplasma mutant strain contains two LoxP sites and one FRT site simultaneously, and the FRT site is located between the two LoxP sites; or contains one LoxP and two FRT sites simultaneously, and the LoxP site is located between the two FRT sites; and the LoxP and FRT sites are located in a non-open reading frame.

[0034] A method for preparing a mycoplasma mutant strain comprises using a transposon to insert two LoxP sites and one FRT site into a non-open reading frame in a mycoplasma genome, wherein the FRT site is located between the two LoxP sites; or inserting one LoxP and two FRT sites, wherein the LoxP site is located between the two FRT sites.

[0035] A vector containing a transposon comprises the following elements: a gene regulatory sequence, a transposase gene sequence, a left-directed terminal inverted repeat sequence, a forward LoxP recognition site, a forward FRT recognition site, a gentamicin resistance gene, and a right-directed terminal inverted repeat sequence.

[0036] A preferred transposase is Tn4001 transposase.

[0037] Optionally, one connection mode of the above elements is: gene regulatory sequence-Tn4001 transposase gene sequence-left terminal inverted repeat sequence-forward LoxP recognition site-forward FRT recognition site-gentamicin resistance gene-forward LoxP recognition site-right terminal inverted repeat sequence.

[0038] Optionally, one connection mode of the above elements is: gene regulatory sequence-Tn4001 transposase gene sequence-left terminal inverted repeat sequence-forward FRT recognition site-forward LoxP recognition site-gentamicin resistance gene-forward FRT recognition site.

[0039] Furthermore, the elements can be connected in any order.

[0040] Preferably, the above elements are inserted into a PUC-SP backbone vector (e.g. Figure 2 The SmaI site of the pTn4001-GmR vector is composed of the pTn4001-GmR vector.

[0041] In the above original documents:

[0042] The gene regulatory sequence is shown in SEQ ID NO.7;

[0043] The Tn4001 transposase gene sequence is shown in SEQ ID NO.8;

[0044] The left terminal inverted repeat sequence is shown in SEQ ID NO.9;

[0045] The forward LoxP recognition site sequence is shown in SEQ ID NO.10;

[0046] The forward FRT recognition site sequence is shown in SEQ ID NO.11;

[0047] The sequence of the gentamicin resistance gene (GmR) is shown in SEQ ID NO.12;

[0048] The right terminal inverted repeat sequence is shown as SEQ ID NO.13.

[0049] Optionally, a pTn4001-GmR vector (such as Figure 3 The full sequence of the element in (as shown) is shown in SEQ ID NO.14.

[0050] Application of the above vector in preparing mycoplasma mutant strains.

[0051] The present invention further provides an application of the mycoplasma mutant strain in preparing a gene-deficient mycoplasma without exogenous gene expression. The gene deletion includes single-base / multi-base deletion and single / multi-gene deletion.

[0052] An optional application is to use gene editing technology to knock out the target gene in the above mutant strain to construct a gene-deficient mycoplasma; then use a recombinase to delete the exogenous gene to obtain a gene-deficient mycoplasma without exogenous gene expression.

[0053] The present invention also provides a method for preparing a single gene-deficient mycoplasma: a recombinant vector is transferred into the aforementioned mycoplasma mutant strain containing both LoxP and FRT sites to obtain a single gene-deficient mycoplasma; the recombinant vector comprises the following elements: a gene regulatory sequence, sgRNA, a gRNA backbone of the CRISPR / Cas9 system of Streptococcus pyogenes, a fibrin terminator, a cytosine base editor (CBE) sequence, a forward FRT or LoxP recognition site, a tetracycline resistance gene, and a pUC replicon (Ori).

[0054] Optionally, one way of connecting the above elements is: gene regulatory sequence-sgRNA-gRNA backbone of the CRISPR / Cas9 system of Streptococcus pyogenes-fibrin terminator-cytosine base editor (CBE) sequence-fibrin terminator-forward FRT recognition site-tetracycline resistance gene-pUC replicon (Ori).

[0055] Optionally, one way of connecting the above elements is: gene regulatory sequence-sgRNA-gRNA backbone of the CRISPR / Cas9 system of Streptococcus pyogenes-fibrin terminator-cytosine base editor (CBE) sequence-fibrin terminator-forward LoxP recognition site-tetracycline resistance gene-pUC replicon (Ori).

[0056] Furthermore, the elements are connected in unrelated sequences.

[0057] Among the above components:

[0058] The gene regulatory sequence is shown in SEQ ID NO.7;

[0059] The gRNA backbone sequence of the Streptococcus pyogenes CRISPR / Cas9 system is shown in SEQ ID NO. 16;

[0060] The fibrin terminator sequence is shown in SEQ ID NO.17;

[0061] The cytosine base editor (CBE) sequence is shown in SEQ ID NO.18;

[0062] The forward LoxP recognition site sequence is shown in SEQ ID NO.10;

[0063] The forward FTR recognition site sequence is shown in SEQ ID NO.11;

[0064] The tetracycline resistance gene (TcR) sequence is shown in SEQ ID NO. 19;

[0065] The sequence of pUC replicon (Ori) is shown in SEQ ID NO. 20;

[0066] The sgRNA sequence is designed according to the gene to be knocked out.

[0067] A recombinant vector in the above method for preparing a single gene deletion type mycoplasma: pCas9-FRT vector (such as Figure 4 as shown).

[0068] A method for preparing a multi-gene deletion type Mycoplasma: designing sgRNAs of the multi-genes to be knocked out, transferring them into the above-mentioned single-gene deletion type Mycoplasma, and knocking out to obtain the multi-gene deletion type Mycoplasma.

[0069] The present invention also provides a method for preparing a gene-deficient mycoplasma without exogenous gene expression: using a recombinase vector to delete the exogenous genes of the single-gene or multi-gene-deficient mycoplasma prepared by the above method. A specific process is as follows Figure 1 shown.

[0070] The recombinase vector is prepared by connecting a gene regulatory sequence and a recombinase gene in series and inserting them into the SmaI site of the PUC-SP vector.

[0071] The recombinase gene includes Cre recombinase gene and FLP recombinase gene.

[0072] Specifically, the Cre recombinase gene is shown as SEQ ID NO.22; the FLP recombinase gene is shown as SEQ ID NO.23.

[0073] In the present invention, the genes described are synthesized by Sangon Biotech (Shanghai) Co., Ltd.

[0074] In the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art.

[0075] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0076] Example 1

[0077] Preparation of mycoplasma competent cells:

[0078] Mycoplasma strains were inoculated in 10 mL of mycoplasma culture medium and cultured at 37°C until the logarithmic growth phase (between 1E7 and 1E8 CCU / mL). The mycoplasma culture was harvested and centrifuged at 12,000 rpm for 15 min at 4°C. The precipitate was resuspended in 10 mL of sterilized electroporation buffer (272 mM Sucrose, 8 mM Hepes) and repeated three times. 10 mL of electroporation buffer was added to the mycoplasma precipitate, the precipitate was thoroughly resuspended, and 100 μL was dispensed into each tube and placed on ice to obtain mycoplasma competent cells.

[0079] Mycoplasma electroporation method:

[0080] Take a certain amount of plasmid and add it to the mycoplasma competent cells, and put it on ice for 10 minutes. Transfer the cells to a pre-cooled 0.2mm electroporation cup and set the electroporation conditions: voltage 1250V, resistance 100Ω, capacitance 25μF, electroporation time 5ms. After electroporation, wash out the electroporated mycoplasma with 1mL of pre-cooled mycoplasma culture medium, mix gently and transfer to a test tube, place at room temperature for 10 minutes, add 2mL of modified KM2 culture medium, and culture at 37℃ for 2h. After the mycoplasma is appropriately diluted, take 100ul and apply it to the mycoplasma agar culture medium containing screening antibiotics, and culture at 37℃ for 5~7d.

[0081] Construction of mycoplasma mutants containing both LoxP and FRT sites:

[0082] Prepare competent cells of Mycoplasma ovipneumoniae (MO_NM01 strain, deposit number CGMCC No.19698, see patent CN202010444611.0) according to the above method, add 10μg of pTn4001-GmR plasmid (the full sequence of the original is shown in SEQID NO.14) to the competent cells, and perform electrotransformation according to the above operation. The transformation product is coated on mycoplasma agar medium containing 10ug / mL of gentamicin and cultured at 37°C for 5~7d. Under an upright microscope, pick a certain number of single colonies with a sterilized toothpick, inoculate them into 1mL of mycoplasma culture medium, and culture at 37°C until the culture medium turns orange-red (about pH 6.7). PCR identification of mycoplasma, primer sequences are shown in SEQ ID NO.1 and 2, PCR product is 531bp (results are shown in Figure 5), the positive identification is the successful transposition of the Mycoplasma ovipneumoniae LoxP-FRT mutant. Then the insertion site is identified, and the primers are respectively used as a combination of SEQ ID NO.1 and random primers, and a combination of SEQ ID NO.2 and random primers, for PCR amplification. The amplified product is analyzed by electrophoresis, and a single band is cut out. After gel recovery, it is sent to Sangon Biotech (Shanghai) Co., Ltd. for sequencing. The PCR reaction conditions are: pre-denaturation at 94℃ for 2min, denaturation at 94℃ for 30s, annealing at 56℃ for 30s, extension at 72℃ for 30s, 30 cycles, and final extension at 72℃ for 5min. The Mycoplasma ovipneumoniae LoxP-FRT mutant whose insertion site is not in the open reading frame (ORF) in the sequencing results is the preferred mutant.

[0083] The results are as follows Figure 8 and 9 As shown, the Mycoplasma LoxP-FRT preferred mutant strain was successfully constructed. Figure 8 Comparison of sequencing results between the original strain and the preferred mutant strain. Fig. 9 The sequencing results of the LoxP-FRT preferred mutant showed that the insertion site was located between the two open reading frames.

[0084] Example 2

[0085] Construction of DnaJ single gene deletion strain:

[0086] sgRNA was designed according to the DnaJ gene, and the sequence is shown in SEQ ID NO.15.

[0087] The LoxP-FRT mutant strain of Mycoplasma ovipneumoniae selected in Example 1 was prepared as competent cells, and 5ug of each FLP recombinase plasmid and pCas9-FRT plasmid containing DnaJ gRNA (the full sequence of the element is shown in SEQ ID NO.21) were added to the competent cells, and electrotransformation was performed according to Example 1. The transformation product was coated on a mycoplasma agar medium containing 10ug / mL of tetracycline and 10ug / mL of gentamicin, and cultured at 37°C for 5-7d. Under an upright microscope, a certain number of single colonies were picked with a sterilized toothpick, inoculated into 1mL of mycoplasma culture medium, and cultured at 37°C until the culture medium turned orange-red (about pH 6.7). PCR identification of mycoplasma, primer sequences are shown in SEQ ID NO.3 and 4, and the PCR product is 1188bp (results are shown in Figure 6 ), the positive ones were identified as the LoxP-FRT mutant strain of Mycoplasma ovipneumoniae that had been recombined with the cytosine base editor (CBE). The sequencing results before and after recombination are shown in Fig.10 After successful recombination, the pCas9-FRT sequence containing tetracycline resistance is recombined into the FRT site.

[0088] The DnaJ gene was further amplified by PCR, the primer sequences are shown in SEQ ID NO. 5 and 6, and the PCR product was 609 bp (the results are shown in Figure 7 ), sequencing was used to identify whether the base editor system was effective and terminated the translation of DnaJ protein prematurely.

[0089] The results are as follows Fig.11 As shown, the translation of DnaJ protein terminates prematurely, which is the DnaJ gene deletion strain of Mycoplasma ovipneumoniae.

[0090] This example only lists one method for constructing a single gene deletion strain. sgRNA can also be designed according to other single gene information to construct corresponding single gene deletion strains.

[0091] Example 3

[0092] Construction of multi-gene deletion strains:

[0093] Design the guide RNA sequence of the corresponding gene, sgRNA is transcribed in vitro or synthesized by a biological company, mixed and electroporated into the Mycoplasma single gene deletion strain obtained in Example 2, and sequenced and verified to be the Mycoplasma multi-gene deletion strain.

[0094] Example 4

[0095] Cre recombinase deletes the inserted gene:

[0096] The DnaJ gene deletion strain of Mycoplasma ovipneumoniae selected in Example 2 was prepared as competent cells, and 10ug of the Cre recombinase plasmid was added to the competent cells, and the electrotransformation was performed according to Example 1. The transformation product was coated on the mycoplasma agar medium without antibiotics and cultured at 37°C for 5-7d. Under an upright microscope, a certain number of single colonies were picked with a sterilized toothpick, inoculated into 1mL mycoplasma culture medium, and cultured at 37°C until the culture medium was orange-red (about pH 6.7). These mycoplasmas were then negatively screened for antibiotics, and inoculated into mycoplasma culture medium containing 10ug / mL of tetracycline and 10ug / mL of gentamicin, and mycoplasma culture medium without antibiotics at a ratio of 1:10, and cultured at 37°C until part of the culture medium was orange-red (about pH 6.7).

[0097] If the mycoplasma does not grow in the medium containing antibiotics and the color of the medium does not change, but the mycoplasma grows in the medium without antibiotics and the color of the medium is orange-red, it is the desired positive mycoplasma. Due to the action of Cre recombinase, the sequence between the two positive LoxP recognition sites of this mycoplasma is deleted. The result is as follows: Fig.12 As shown, the sequencing results showed that most of the exogenous genes were successfully deleted, no additional exogenous proteins were expressed, and there was no antibiotic resistance, which could meet the screening requirements for mycoplasma live vaccine candidate strains.

[0098] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing a single gene-deficient Mycoplasma ovipneumoniae, characterized in that: The FLP recombinase plasmid and the recombinant vector were transferred into the mutant strain of Mycoplasma ovipneumoniae to construct a single gene deletion type of Mycoplasma ovipneumoniae. The recombinant vector includes the following elements: gene regulatory sequence-sgRNA-gRNA backbone of the CRISPR / Cas9 system of Streptococcus pyogenes-fibrin terminator-cytosine base editor sequence-fibrin terminator-forward FRT recognition site-tetracycline resistance gene-pUC replicon; The preparation method of the Mycoplasma ovipneumoniae mutant strain is as follows: using a vector containing a transposon to insert two LoxP sites and one FRT site into a non-open reading frame in the Mycoplasma ovipneumoniae genome, wherein the FRT site is located between the two LoxP sites; The transposon-containing vector uses PUC-SP as a backbone vector and inserts the following elements into the SmaI site: gene regulatory sequence-Tn4001 transposase gene sequence-left terminal inverted repeat sequence-forward LoxP recognition site-forward FRT recognition site-gentamicin resistance gene-forward LoxP recognition site-right terminal inverted repeat sequence; The gene regulatory sequence is shown in SEQ ID NO.7; the transposase is Tn4001 transposase, and the gene sequence is shown in SEQ ID NO.8; the left-terminal inverted repeat sequence is shown in SEQ ID NO.9; the forward LoxP recognition site sequence is shown in SEQ ID NO.10; the forward FRT recognition site sequence is shown in SEQ ID NO.11; the gentamicin resistance gene sequence is shown in SEQ ID NO.12; and the right-terminal inverted repeat sequence is shown in SEQ ID NO.

13.

2. A method for preparing a multi-gene deleted Mycoplasma ovipneumoniae, characterized in that: Construct a sgRNA vector of multiple genes to be knocked out, transfer it into the single gene-deleted Mycoplasma ovipneumoniae prepared by the method as claimed in claim 1, and obtain a multi-gene-deleted Mycoplasma ovipneumoniae by gene knockout.

3. A method for preparing a gene-deficient Mycoplasma ovipneumoniae without exogenous gene expression, characterized in that: The vector containing the recombinase is transferred into the Mycoplasma ovipneumoniae prepared by the method of claim 1 or 2, and the exogenous gene is deleted by using the recombinase.